Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on February 4, 2022, primarily to furnish its fourth quarter and full-year 2021 financial results. The report includes the earnings press release (Exhibit 99.1), supplemental financial information (Exhibit 99.2), and a presentation (Exhibit 99.3) related to its financial and operating initiatives. These documents provide key performance indicators and strategic insights for investors. Investors should review the furnished exhibits, particularly the earnings press release and supplemental information, for detailed financial performance, including revenue, profitability, and any forward-looking guidance. The accompanying presentation offers further context on the company's strategic direction and operational updates. It is important to note that some information presented may be non-GAAP financial measures, with reconciliations provided in the supplemental information and the earnings release.
Key Highlights
- 1BMY announced its Q4 and full-year 2021 financial results on February 4, 2022, via an 8-K filing.
- 2The filing includes the official earnings press release (Exhibit 99.1), providing detailed financial performance data.
- 3Supplemental financial information (Exhibit 99.2) is furnished, offering additional data and insights.
- 4A presentation (Exhibit 99.3) on financial and operating initiatives was also provided, accompanied by a conference call and webcast.
- 5The company utilized non-GAAP financial information, with reconciliations available in the supplemental information and earnings release.
- 6This 8-K serves as a key source for understanding BMY's recent financial health and strategic updates.